Table 1

Demographic and disease characteristics and time on treatment in the PRISMS-15 cohort, by original randomisation group (see also online supplementary tables S4 and S5 for characteristics at 24 and 48 months after randomisation)

 Original randomisation group
IFN β-1a, 44 µg sc tiw
(n=95)
IFN β-1a, 22 µg sc tiw
(n=95)
Placebo
(n=100)
Overall
(N=290)
Female, n (%)63 (66.3)65 (68.4)76 (76.0)204 (70.3)
White, n (%)94 (98.9)94 (98.9)99 (99.0)287 (99.0)
At baseline
 Median (range) time from MS onset, years7.0 (0.6–34.4)5.9 (1.0–22.8)4.6 (1.2–18.8)5.6 (0.6–34.4)
 Mean (SD) number of relapses in prior 2 years3.0 (1.1)3.0 (1.1)3.1 (1.3)3.0 (1.2)
 Mean (SD) EDSS score2.5 (1.2)2.4 (1.2)2.2 (1.2)2.4 (1.2)
At PRISMS-15
 Median (range) age, years52.3 (35.4–66.4)50.3 (36.9–66.1)51.1 (36.2–64.6)51.2 (35.4–66.4)
 Mean (SD) time on sc IFN β-1a treatment, years10.6 (5.0)10.6 (4.9)8.8 (5.1)10.0 (5.0)
  • EDSS, Expanded Disability Status Scale; IFN, interferon; MS, multiple sclerosis; sc, subcutaneous(ly); tiw, three times weekly.